This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Investors Undervaluing Methode (MEI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Methode (MEI) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Methode (MEI) delivered earnings and revenue surprises of -12.99% and -0.37%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Methode (MEI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Methode (MEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Methode (MEI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Methode (MEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Methode (MEI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 of the Best Stocks to Buy for a Post-Pandemic Rally
by Tirthankar Chakraborty
The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.
Should Value Investors Buy Methode (MEI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Must-Buy Electronics Stocks to Beat Coronavirus Woes
by Radhika Pujara
Investors can bet on SMTC Corporation (SMTX) and four other strong buy Electronics stocks that have strong fundamentals for a winning portfolio despite coronavirus concerns.
Should Value Investors Choose Methode Electronics Now (MEI)?
by Zacks Equity Research
Let's see if Methode Electronics (MEI) stock is a good choice for value-oriented investors right now from multiple angles.
Top Ranked Value Stocks to Buy for March 31st
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, March 31st
Looking for Value? Why It Might Be Time to Try Methode Electronics (MEI)
by Zacks Equity Research
Methode Electronics (MEI) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Methode Electronics (MEI) Up on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Methode Electronics (MEI) gains more than 2% on Mar 5 after the company's Q3 top- and bottom-line numbers exceed expectations and mark year-over-year improvement as well.
Company News for Mar 6, 2020
by Zacks Equity Research
Companies in the news are: XRX, CIEN, VIPS, MEI
Methode (MEI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Methode (MEI) delivered earnings and revenue surprises of 14.13% and 1.90%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Methode Electronics (MEI) in Q3 Earnings?
by Zacks Equity Research
Methode Electronics' (MEI) third-quarter fiscal 2020 results are expected to suffer due to strike at General Motors and currency rate fluctuations.
Methode (MEI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Methode (MEI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Methode Electronics Enters Oversold Territory
by Zacks Equity Research
Methode Electronics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
How Does This Frothy Stock Market Run End?
by John Blank
This is a question worth answering, with care.
Where Is the Top to This Stock Market Run? Zacks JAN Strategy
by John Blank
It is commonplace to acknowledge the role of the U.S. Fed lifting stock markets the last three months. But earnings outlooks drawn up on the last quarter of 2019 are not improving.
Itron (ITRI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Itron (ITRI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Methode Electronics (MEI) Stock Might be a Great Pick
by Zacks Equity Research
Methode Electronics (MEI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Should Value Investors Buy Methode (MEI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Methode Electronics (MEI) Q2 Earnings & Sales Miss Estimates
by Zacks Equity Research
Methode Electronics' (MEI) second-quarter fiscal 2020 results suffer from strike at General Motors and currency rate fluctuations.
New Strong Sell Stocks for December 6th
by Zacks Equity Research
Here are 3 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Methode (MEI) Tops Q2 Earnings Estimates
by Zacks Equity Research
Methode (MEI) delivered earnings and revenue surprises of 25.49% and -6.63%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?